Advanced Genomics has developed technology that unlocks secrets of genes and raking in the big bucks for the development of better diagnostics, safe and cost effective drugs and personalized treatment procedures. Our product development pipeline includes early research which encompasses the entire spectrum of genomic biomarkers discovery, predictive diagnosis, and analysis of drug response and drug toxicity. The development phase of this pipeline will slowly expand to drug discovery and development of DNA based clinical diagnostics.

Our unique and powerful genomics and bioinformatics tools and database are designed to characterize disease pathways and identify lead candidates for biomarker discovery of chronic diseases like cancers of , as well as emerging and re-emerging infectious diseases.

Disease Pathway

Biomarker Discovery

Fighting with Infectious diseases: Infectious diseases remain the leading cause of death worldwide despite advances in medical research. Globalization, increasing trade, changes in human demographics, behavior, etc. bring people into closer and more frequent contact with pathogens. These changing trends remain the leading causes of the emergence and reemergence of infectious diseases. Improper use of antibiotics has led to the development of resistant pathogens that are untreatable with standard treatment procedures.

Advanced genomics is collaborating at a global scale with hospitals and research institutes to identify better control strategies by using genomics and post-genomics research. With two decades of experience of characterizing various pathogens and host-pathogen interactions at the molecular level, Advanced Genomics is well positions to rapidly deploy its proven technology to respond to infectious diseases. Our main focus of research is on Zoonotic diseases and will slowly expand to other areas. Technology developed by Advanced Genomics is being used to get following information:

1. Gene expression signatures of various pathogens within the host and then compare those signatures.
2. Genomic content of various strains is compared to reference strain to identify conservation of virulence genes among various strains indicate that pathogen possess basic pathogenesis mechanism that confers an opportunistic infection capability
3. Whole-genome expression analysis in virulent and avirulent strains is performed to identify differentially expressed defense genes and pathogen genes in host
4. Sequencing and post-genomic research of emerging disease agents/vector, to reveal genetic basis for microbial/vector evolution, adaptation, and pathogenicity
5. Gene expression signatures to study host-pathogen interaction and mechanism of virulence
6. Whole-genome expression analysis  to view complete progression of an infectious disease state

Advanced Genomics at Research and Discovery Platform